Related Experiment Video

Updated: Jun 18, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

Personalized antiplatelet therapy for coronary artery disease patients: is this the future?

Laurent Bonello1, Gilles Lemesle, Axel De Labriolle

  • 1Pôle de cardiologie, Hôpital Universitaire Nord, Chemin des Bourrely, 13015 Marseille, France. laurentbonello@yahoo.fr

Expert Review of Cardiovascular Therapy
|December 4, 2009
PubMed

Insights

Clopidogrel reduces thrombotic events after coronary intervention but has limitations. Optimizing antiplatelet therapy with higher doses or new agents may improve outcomes and personalize treatment.

Area of Science:

  • Cardiology
  • Pharmacology
  • Thrombosis Research

Background:

  • Clopidogrel is effective in reducing thrombotic events post-percutaneous coronary intervention.
  • Limitations in clopidogrel's efficacy persist, leading to ongoing adverse events.
  • Current research explores enhanced platelet inhibition to mitigate risks.

Purpose of the Study:

  • To review strategies for improving antiplatelet therapy in patients undergoing percutaneous coronary intervention.
  • To discuss the potential of higher or tailored clopidogrel dosing and novel antiplatelet agents.
  • To highlight the role of platelet function assays in personalizing antiplatelet treatment.

Main Methods:

  • Literature review of recent studies on clopidogrel and alternative antiplatelet strategies.
  • Analysis of data regarding platelet reactivity inhibition and clinical outcomes.
  • Examination of the impact of new antiplatelet agents and diagnostic assays.

Main Results:

  • Higher or tailored doses of clopidogogrel may enhance platelet inhibition.
  • Novel antiplatelet agents show promise in improving efficacy.
  • Platelet function assays are crucial for guiding personalized therapy.

Conclusions:

  • Optimizing antiplatelet therapy is key to reducing adverse events in interventional cardiology.
  • Personalized antiplatelet treatment strategies are emerging as a significant advancement.
  • The integration of new agents and assays will likely transform clinical practice.

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...